

8th November 2017

To,

Manager - DSC

BSE Limited,

Floor 25, P J Towers,

Dalal Street, Mumbai – 400 001

Subject: Outcome of Board Meeting held on 8th November, 2017

Ref.: Scrip Code: 536456. Scrip ID: RJBIOTECH

Dear Sir,

As required under Regulation 33 and all other applicable regulations, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find attached herewith the Standalone Un-audited Financial Results for the Half Year ended on 30th September, 2017 of the Company along with the Limited Review Report of the Statutory Auditors, M/s Ashok Patil & Associates for the Half Year ended on 30th September, 2017.


The meeting of Board of Directors Commenced at 12.00 p.m and concluded at 2.30 p.m.


Kindly take the same on record and acknowledge the receipt

Thanking You,

Yours Truly,

For R J BIO-TECH LIMITED


Neha Agrawal
(Company Secretary)



Registered Office : Siddharth Arcade, Railway Station Road, Aurangabad - 431 005. (M.S.) India Tel. : +91-240-02354912 to 17 Fax : +91-240-2332111
E-mail : info@rjbiotech.com www.rjbiotech.com CIN No. : L24234MH2005PLC158420.

R J BIO-TECH LIMITED

CIN : L24234MH2005PLC158420


Statement of Assets and Liabilities as on 30th September, 2017

Particulars	(Rs. in Lacs)	
	As at (Current half year) 30-09-2017	As at (Previous year end) 31-03-2017
	Unaudited	Audited
I] EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	946.76	946.76
(b) Reserves & Surplus	(186.88)	148.54
(c) Money received against share warrants	-	-
Total Shareholders Fund	759.88	1,095.30
(2) Share Application money pending allotment		
(3) Non-Current Liabilities		
(a) Long-term Borrowings	304.17	146.50
(b) Deffered Tax Liabilities (Net)	-	-
(c) Other Long term Liabilities	81.57	84.71
(d) Long-term Provisions	-	-
Total Non-Current Liabilities	385.73	231.21
(4) Current Liabilities		
(a) Short-Term Borrowings	2,941.03	2,756.66
(b) Trade Payables	268.34	186.69
(c) Other Current Liabilities	253.33	422.77
(d) Short-Term Provisions	80.18	60.52
Total Current Liabilities	3,542.87	3,426.64
TOTAL	4,688.48	4,753.15
II] ASSETS		
(1) Non Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	193.69	195.23
(ii) Intangible Assets	0.29	0.05
(iii) Capital Work-in-progress	-	-
(iv) Intangible Assets under Development	-	-
Total Fixed Asset	193.98	195.28
(b) Non-Current Investments	-	-
(c) Deffered tax Assets (Net)	-	-
(d) Long-term loans & Advances	32.64	32.64
(e) Other non-Current assets	163.88	174.72
Total Non-Current Assets	390.51	402.64
(2) Current Assets		
(a) Current Investments	-	-
(b) Inventories	2,325.40	2,352.34
(c) Trade Receivables	1,879.22	1,897.59
(d) Cash & Cash equivalents	5.40	3.74
(e) Short-term loans and advances	82.38	75.97
(f) Other current assets	5.57	20.87
Total Current Assets	4,297.97	4,350.51
TOTAL	4,688.48	4,753.15

Note:

01. The Unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 08/11/2017.
02. There were no Investor Complaints received / pending as on 30/09/2017.
03. The Company does not have more than one reportable primary segment in terms of Accounting Standard 17 (AS 17 - Segment Reporting) issued by ICAI/Company (Accounting Standards) Rules, 2006. Therefore, the Company is not required to submit separate segment wise report.
04. Figures of the previous have been re-grouped / re-arranged wherever considered necessary.

Date: 08.11.2017
Place: Aurangabad



For R J Bio-Tech Limited

Raghavendra Joshi
(Director)
DIN. 00307124

Registered Office : Siddharth Arcade, Railway Station Road, Aurangabad - 431 005. (M.S.) India Tel. : +91-240-02354912 to 17 Fax : +91-240-2332111
E-mail : info@rjbiotech.com www.rjbiotech.com CIN No. : L24234MH2005PLC158420.

R J BIO-TECH LIMITED
CIN : L24234MH2005PLC158420

Statement of Unaudited Financial Results for the half year ended 30th September , 2017

(Rs. in Lakhs)


Sr.No.	Particulars	6 Months Ended 30.09.2017	Preceding 6 Months Ended 31.03.2017	Corresponding 6 Months Ended 30.09.2016	Year to date Figures for current period ended 30.09.2017	Year to date Figures for Previous period ended 30.09.2016	Previous year ended 31.03.2017
		Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
01.	Income						
	Revenue From Operations (Net of Excise Duty) (Refer Note No.1)	714.64	9.47	1,564.37	714.64	1,564.37	1,573.83
	Other Income	2.72	-	-	2.72	-	-
	Total Revenue	717.37	9.47	1,564.37	717.37	1,564.37	1,573.83
02.	Expenditure						
a.	Cost of Material Consumed (Refer Note No.2)	332.33	287.69	746.52	332.33	746.52	1,034.20
b.	Purchase of Stock in trade						
c.	Change in inventories of finished goods, work in progress and stock in trade (Refer Note No.3)	70.07	274.79	(62.60)	70.07	(62.60)	212.20
d.	Employee benefit Expenses	75.16	64.55	69.20	75.16	69.20	133.75
e.	Finance Costs	188.65	194.07	166.02	188.68	166.02	360.10
f.	Depreciation and amortization expenses	8.04	14.97	16.84	8.04	16.84	31.81
g.	Other expenses - (Refer Note No.4)	378.54	454.92	854.25	378.54	854.25	1,309.17
	Total	1,052.79	1,290.99	1,790.24	1,052.82	1,790.24	3,081.23
03.	Profit / (Loss) before Exceptional Items and extraordinary items (1-2) and tax	(335.42)	(1,281.53)	(225.87)	(335.45)	(225.87)	(1,507.40)
04.	Exceptional Items	-	(0.04)	5.75	-	5.75	5.71
05.	Profit / (Loss) before extraordinary items and tax (3-4)	(335.42)	(1,281.57)	(220.12)	(335.45)	(220.12)	(1,501.69)
06.	Extraordinary Items	-	-	-	-	-	-
07.	Profit/(Loss) before Tax (5-6)	(335.42)	(1,281.57)	(220.12)	(335.42)	(220.12)	(1,501.69)
08.	Tax Expenses	-	0.01	-	-	-	0.01
09.	Profit / (Loss) for the period from continuing operations (7-8)	(335.42)	(1,281.59)	(220.12)	(335.42)	(220.12)	(1,501.70)
10.	Profit / (Loss) from discontinuing Operations	-	-	-	-	-	-
11.	Tax Expenses of discontinuing Operations	-	-	-	-	-	-
12.	Net Profit/ (Loss) from discontinuing operations (after tax (10-11))	-	-	-	-	-	-
13.	Profit / (Loss) for period before minority interest	(335.42)	(1,281.59)	(220.12)	(335.42)	(220.12)	(1,501.70)



Registered Office : Siddharth Arcade, Railway Station Road, Aurangabad - 431 005. (M.S.) India Tel. : +91-240-02354912 to 17 Fax : +91-240-2332111
E-mail : info@rjbiotech.com www.rjbiotech.com **CIN No. :** L24234MH2005PLC158420.

Sr.No.	Particulars	6 Months Ended 30.09.2017	Preceding 6 Months Ended 31.03.2017	Corresponding 6 Months Ended 30.09.2016	Year to date Figures for current period ended 30.09.2017	Year to date Figures for Previous period ended 30.09.2016	Previous year ended 31.03.2017
		Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
14.	Share of profit /(Loss) of associates	-	-	-	-	-	-
15.	Minority Interest	-	-	-	-	-	-
16.	Net Profit/ (Loss) for the period	(335.42)	(1,281.59)	(220.12)	(335.42)	(220.12)	(1,501.70)
17.	Details of Equity Share Capital						
	Paid Up Equity Share Capital	946.76	946.76	946.76	946.76	946.76	946.76
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
18.	Reserve excluding Revaluation Reserve as per Balance Sheet of Previous Accounting Year	(186.88)	847.57	1,430.13	(186.88)	1,430.13	148.54
19.	Earning Per Share (EPS)						
	(a) Basic & diluted EPS before Extraordinary items for the Period, for the year to date & for the previous year (not to be annulised)	(3.54)	(27.15)	(2.32)	(3.54)	(2.32)	(15.86)
	(b) Basic & diluted EPS after Extraordinary items for the Period, for the year to date & for the previous year (not to be annulised)	(3.54)	(27.15)	(2.32)	(3.54)	(2.32)	(15.86)

Place: Aurangabad
Date: 08.11.2017



For R J Bio-Tech Limited

Raghavendra Joshi
(Director)
DIN. 00307124



LIMITED REVIEW REPORT


To,
The Board of Directors of
R J Bio-Tech Limited.
"Siddharth Arcade", Opp. Holiday Camp, Station Road,
Aurangabad - 431 005

1. We have reviewed the accompanying statement of unaudited financial results of 'R J Bio-Tech Limited' ('the Company'), for the Half Year ended **30.09.2017**. ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. **Basis for Qualified Conclusion:**
 - a. The management has provided statement of closing inventories as on 30.09.2017 giving particulars, quantity & value but no supporting records regarding physical verification of inventories & working of realizable value thereof is provided for our verification. Accordingly, we are unable to satisfy ourselves by alternative means concerning the inventory quantities and values held at Sept 30, 2017 which are stated in the unaudited financial results at Rs. 23,25,40,416/-.
 - b. In the absence of confirmations from debtors we are unable to confirm or verify by alternative means accounts receivable included in the unaudited Financial Statements at a total amount of Rs.20,90,05,924/- (before opening provision for bad & doubtful debts of Rs. 210,84,300/-) as at Sept 30, 2017.

As a result of these matters, we are unable to determine whether any adjustment might have been found necessary in respect of recorded receivables & inventories in the unaudited financial results.
- c. Based on our Limited Review conducted and on the basis of information & explanations given by the management & on the basis of documents examined by us, the company has defaulted in repayment of loans including unapplied interest thereon aggregating to Rs. 29,98,81,302/- taken from State Bank of India in the form of Working Capital & Term Loans; the same accounts has been already classified as Non Performing Assets by the bank.
4. Except the possible effects of the matters specified under "Basis for Qualified Conclusion" & based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Aurangabad
Date: 08.11.2017

For Ashok Patil & Associates
Chartered Accountants
Firm Reg. No. 122045W



(Ashok Patil)
Partner
M.No.131344